{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T17:16:46Z","timestamp":1788283006706,"version":"build-2803163510"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ajo.2026.06.043","type":"journal-article","created":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T21:52:00Z","timestamp":1782683520000},"page":"329-342","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Aflibercept With Versus Without Reduced-Fluence Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: Optical Coherence Tomography Angiographic Changes From a Randomized Clinical Trial"],"prefix":"10.1016","volume":"290","author":[{"given":"KELVIN YC","family":"TEO","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1123-0079","authenticated-orcid":false,"given":"NOA","family":"GILEAD","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ZEHUA","family":"JIANG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8798-066X","authenticated-orcid":false,"given":"YU JEAT","family":"CHONG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ANNA","family":"TAN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4660-1739","authenticated-orcid":false,"given":"HIOK H","family":"CHAN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"FARAH NI","family":"IBRAHIM","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5356-7604","authenticated-orcid":false,"given":"BEAU J","family":"FENNER","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"CHARLES","family":"ONG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"CHRIS","family":"SUN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3358-3516","authenticated-orcid":false,"given":"CHUI MING GEMMY","family":"CHEUNG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ajo.2026.06.043_bib0001","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.ophtha.2017.11.019","article-title":"Polypoidal choroidal vasculopathy: definition, pathogenesis, diagnosis, and management","volume":"125","author":"Cheung","year":"2018","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.ajo.2026.06.043_bib0002","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.oret.2023.11.001","article-title":"Polypoidal Choroidal Vasculopathy","volume":"8","author":"Teo","year":"2024","journal-title":"Ophthalmol Retina"},{"issue":"1","key":"10.1016\/j.ajo.2026.06.043_bib0003","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/IAE.0000000000003285","article-title":"Optical coherence tomography features of polypoidal lesion closure in polypoidal choroidal vasculopathy treated with aflibercept","volume":"42","author":"Tan","year":"2022","journal-title":"Retina"},{"issue":"11","key":"10.1016\/j.ajo.2026.06.043_bib0004","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1097\/IAE.0000000000003595","article-title":"Predictors and importance of complete polypoidal lesion regression in the EVEREST II study: predictors of polyp regression in polypoidal choroidal vasculopathy","volume":"42","author":"Tan","year":"2022","journal-title":"Retina"},{"issue":"1","key":"10.1016\/j.ajo.2026.06.043_bib0005","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/s41598-018-37384-y","article-title":"Characterizing branching vascular network morphology in polypoidal choroidal vasculopathy by optical coherence tomography angiography","volume":"9","author":"Huang","year":"2019","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.ajo.2026.06.043_bib0006","article-title":"Clinical features and prognosis of polypoidal choroidal vasculopathy with different morphologies of branching vascular network on optical coherence tomography angiography","volume":"11","author":"Ma","year":"2021","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.ajo.2026.06.043_bib0007","first-page":"165","article-title":"New concepts in polypoidal choroidal vasculopathy imaging: a focus on optical coherence tomography and optical coherence tomography angiography","volume":"8","author":"Teo","year":"2019","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"issue":"9","key":"10.1016\/j.ajo.2026.06.043_bib0008","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1097\/IAE.0000000000001776","article-title":"Comparison of optical coherence tomography angiographic changes after anti-vascular endothelial growth factor therapy alone or in combination with photodynamic therapy in polypoidal choroidal vasculopathy","volume":"38","author":"Teo","year":"2018","journal-title":"Retina"},{"issue":"1","key":"10.1016\/j.ajo.2026.06.043_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.xops.2021.100082","article-title":"Evolution of polypoidal lesions after treatment of polypoidal choroidal vasculopathy","volume":"2","author":"Tan","year":"2022","journal-title":"Ophthalmol Sci"},{"issue":"7","key":"10.1016\/j.ajo.2026.06.043_bib0010","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1007\/s00417-022-05583-z","article-title":"Quantitative analysis of branching neovascular networks in polypoidal choroidal vasculopathy by optical coherence tomography angiography after photodynamic therapy and anti-vascular endothelial growth factor combination therapy","volume":"260","author":"Wang","year":"2022","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"7","key":"10.1016\/j.ajo.2026.06.043_bib0011","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-050252","article-title":"Multicentre, randomised clinical trial comparing intravitreal aflibercept monotherapy versus aflibercept combined with reduced-fluence photodynamic therapy (rf-pdt) for the treatment of polypoidal choroidal vasculopathy","volume":"11","author":"Vyas","year":"2021","journal-title":"BMJ Open"},{"issue":"5","key":"10.1016\/j.ajo.2026.06.043_bib0012","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1001\/jamaophthalmol.2025.0250","article-title":"Aflibercept with vs without reduced-fluence photodynamic therapy for polypoidal choroidal vasculopathy: a randomized clinical trial","volume":"143","author":"Chong","year":"2025","journal-title":"JAMA Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2026.06.043_bib0013","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.oret.2020.07.005","article-title":"Morphologic predictors and temporal characteristics of conversion from nonexudative to exudative age-related macular degeneration in the fellow eye","volume":"5","author":"Teo","year":"2021","journal-title":"Ophthalmol Retina"},{"issue":"11","key":"10.1016\/j.ajo.2026.06.043_bib0014","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1001\/jamaophthalmol.2017.4030","article-title":"Efficacy and safety of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: a randomized clinical trial","volume":"135","author":"Koh","year":"2017","journal-title":"JAMA Ophthalmol"},{"issue":"10","key":"10.1016\/j.ajo.2026.06.043_bib0015","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1007\/s00417-016-3333-y","article-title":"EVEREST study report 3: diagnostic challenges of polypoidal choroidal vasculopathy. Lessons learnt from screening failures in the EVEREST study","volume":"254","author":"Tan","year":"2016","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajo.2026.06.043_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.apjo.2025.100144","article-title":"Consensus and guidelines on diagnosis and management of polypoidal choroidal vasculopathy (PCV) from the asia-pacific vitreo-retina society (APVRS)","volume":"14","author":"Ruamviboonsuk","year":"2025","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"issue":"2","key":"10.1016\/j.ajo.2026.06.043_bib0017","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41433-021-01688-7","article-title":"Evolving treatment paradigms for PCV","volume":"36","author":"Fenner","year":"2022","journal-title":"Eye (Lond)"},{"issue":"3","key":"10.1016\/j.ajo.2026.06.043_bib0018","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ophtha.2020.08.006","article-title":"Polypoidal choroidal vasculopathy: consensus nomenclature and non-indocyanine green angiograph diagnostic criteria from the Asia-pacific ocular imaging society PCV workgroup","volume":"128","author":"Cheung","year":"2021","journal-title":"Ophthalmology"},{"issue":"10","key":"10.1016\/j.ajo.2026.06.043_bib0019","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.oret.2021.04.002","article-title":"Non-ICGA treatment criteria for suboptimal anti-VEGF response for polypoidal choroidal vasculopathy: APOIS PCV workgroup report 2","volume":"5","author":"Chong Teo","year":"2021","journal-title":"Ophthalmol Retina"},{"issue":"5","key":"10.1016\/j.ajo.2026.06.043_bib0020","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1097\/APO.0000000000000551","article-title":"Optical coherence tomography features for identifying posttreatment complete polypoidal regression in polypoidal choroidal vasculopathy","volume":"11","author":"Chaikitmongkol","year":"2022","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"issue":"2","key":"10.1016\/j.ajo.2026.06.043_bib0021","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/IAE.0000000000002902","article-title":"Ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: predictors of visual and anatomical response in the EVEREST II study","volume":"41","author":"Cheung","year":"2021","journal-title":"Retina"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939426003521?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939426003521?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T16:32:25Z","timestamp":1788280345000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939426003521"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":21,"alternative-id":["S0002939426003521"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2026.06.043","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aflibercept With Versus Without Reduced-Fluence Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: Optical Coherence Tomography Angiographic Changes From a Randomized Clinical Trial","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2026.06.043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}